Debt-to-equity of Syndax Pharmaceuticals Inc from 30 Sep 2016 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Syndax Pharmaceuticals Inc quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 31 Dec 2025.
  • Syndax Pharmaceuticals Inc Debt-to-equity for the quarter ending 31 Dec 2025 was 320%, a 757% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Syndax Pharmaceuticals Inc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 320% +282% +757% 31 Dec 2025
Q3 2025 224% +212% +1852% 30 Sep 2025
Q2 2025 132% +122% +1166% 30 Jun 2025
Q1 2025 74% +64% +637% 31 Mar 2025
Q4 2024 37% +28% +323% 31 Dec 2024
Q3 2024 11% +3.9% +52% 30 Sep 2024
Q2 2024 10% +3.9% +60% 30 Jun 2024
Q1 2024 10% +2.5% +34% 31 Mar 2024
Q4 2023 8.8% -0.48% -5.2% 31 Dec 2023
Q3 2023 7.6% -2.9% -28% 30 Sep 2023
Q2 2023 6.5% -6.4% -50% 30 Jun 2023
Q1 2023 7.5% -7.4% -50% 31 Mar 2023
Q4 2022 9.3% -8% -46% 31 Dec 2022
Q3 2022 10% -11% -51% 30 Sep 2022
Q2 2022 13% -11% -45% 30 Jun 2022
Q1 2022 15% -10% -41% 31 Mar 2022
Q4 2021 17% -16% -47% 31 Dec 2021
Q3 2021 21% -27% -56% 30 Sep 2021
Q2 2021 24% -34% -59% 30 Jun 2021
Q1 2021 25% -55% -68% 31 Mar 2021
Q4 2020 33% -31% -48% 31 Dec 2020
Q3 2020 48% -8.8% -15% 30 Sep 2020
Q2 2020 58% +5.9% +11% 30 Jun 2020
Q1 2020 80% +30% +60% 31 Mar 2020
Q4 2019 64% +16% +33% 31 Dec 2019
Q3 2019 57% +16% +40% 30 Sep 2019
Q2 2019 52% +16% +45% 30 Jun 2019
Q1 2019 50% +20% +68% 31 Mar 2019
Q4 2018 48% +19% +65% 31 Dec 2018
Q3 2018 41% +12% +44% 30 Sep 2018
Q2 2018 36% +8.4% +30% 30 Jun 2018
Q1 2018 30% +3.2% +12% 31 Mar 2018
Q4 2017 29% +5.7% +24% 31 Dec 2017
Q3 2017 28% -120% -81% 30 Sep 2017
Q2 2017 28% 30 Jun 2017
Q1 2017 27% 31 Mar 2017
Q4 2016 23% 31 Dec 2016
Q3 2016 148% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.